Business Description
Noxopharm Ltd
ISIN : AU000000NOX9
Total Employee Number:
17Description
Noxopharm Ltd is an Australian clinical-stage drug development company focused on discovering and developing novel treatments for cancer and inflammation, as well as improving mRNA vaccines, based on two preclinical platforms. It is engaged in one segment which is the clinical development in the field of both oncology and non-oncology in the pan-pacific region.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.03 | |||||
Equity-to-Asset | -0.24 | |||||
Debt-to-Equity | -2.94 | |||||
Debt-to-EBITDA | -0.73 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 38 | |||||
3-Year EPS without NRI Growth Rate | 35.7 | |||||
3-Year FCF Growth Rate | 24.8 | |||||
3-Year Book Growth Rate | -71.1 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 45.99 | |||||
9-Day RSI | 50.78 | |||||
14-Day RSI | 53.26 | |||||
3-1 Month Momentum % | 32.76 | |||||
6-1 Month Momentum % | -12.5 | |||||
12-1 Month Momentum % | 60.42 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.81 | |||||
Quick Ratio | 0.81 | |||||
Cash Ratio | 0.02 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -423.75 | |||||
ROA % | -111.3 | |||||
ROIC % | -295.27 | |||||
3-Year ROIIC % | -88.49 | |||||
ROC (Joel Greenblatt) % | -597.77 | |||||
ROCE % | -345.73 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -6.44 | |||||
EV-to-EBITDA | -6.44 | |||||
EV-to-FCF | -4.29 | |||||
Earnings Yield (Greenblatt) % | -15.54 | |||||
FCF Yield % | -27.86 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Noxopharm Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | |||
| EPS (TTM) (A$) | -0.019 | ||
| Beta | -2.3878 | ||
| 3-Year Sharpe Ratio | 0.55 | ||
| 3-Year Sortino Ratio | 1.57 | ||
| Volatility % | 108.2 | ||
| 14-Day RSI | 53.26 | ||
| 14-Day ATR (A$) | 0.005645 | ||
| 20-Day SMA (A$) | 0.087425 | ||
| 12-1 Month Momentum % | 60.42 | ||
| 52-Week Range (A$) | 0.046 - 0.135 | ||
| Shares Outstanding (Mil) | 307.24 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Noxopharm Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Noxopharm Ltd Stock Events
| Event | Date | Price (A$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Noxopharm Ltd Frequently Asked Questions
What is Noxopharm Ltd(ASX:NOX)'s stock price today?
The current price of ASX:NOX is A$0.09. The 52 week high of ASX:NOX is A$0.14 and 52 week low is A$0.05.
When is next earnings date of Noxopharm Ltd(ASX:NOX)?
The next earnings date of Noxopharm Ltd(ASX:NOX) is .
Does Noxopharm Ltd(ASX:NOX) pay dividends? If so, how much?
Noxopharm Ltd(ASX:NOX) does not pay dividend.
Press Release
Articles on Noxopharm Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers